10.1 Intervention, Referral & Follow-Up

Key Takeaways

  • Intervention and/or referral is the fourth APhA/NACDS core element: the pharmacist or qualified provider acts on medication-related problems with the patient and/or other clinicians.
  • Referrals send the patient to another professional or setting when the needed action is outside the MTM provider’s scope or when specialty care is required.
  • Documentation and follow-up closes the loop—recording what was done and verifying outcomes, adherence to the MAP, and unresolved problems on a planned timeline.
  • Technicians track pending interventions, schedule follow-ups, log outreach attempts, and escalate non-responses; they do not independently decide therapy changes or clinical referrals.
  • CMS Part D MTM programs must offer interventions for both beneficiaries and prescribers, and must perform quarterly TMRs with follow-up interventions when necessary.
Last updated: August 2026

10.1 Intervention, Referral & Follow-Up

Quick Answer: After the MTR finds problems and the PMR/MAP are updated, the team must act (intervention and/or referral) and then prove and recheck (documentation and follow-up). Technicians keep the queue moving—tracking messages, due dates, and outreach—while pharmacists own clinical decisions.

Chapter 9 covered the first three APhA/NACDS core elements (MTR, PMR, MAP). This section finishes the model: intervention and/or referral (element 4) and the follow-up half of documentation and follow-up (element 5). Domain 3 (MTM Administration & Management, 24%) tests whether you know that identifying a problem is not enough—someone must intervene, refer when needed, document the work, and follow up until the issue is resolved or deliberately closed.


Why These Elements Exist

An MTR that discovers a dangerous NSAID in heart failure is useless if nobody contacts the prescriber, nobody updates the patient’s MAP, and nobody calls back to confirm the NSAID stopped. The APhA/NACDS model treats action and continuity as formal core elements—not optional extras after “the consult.”

In Medicare Part D MTM, CMS reinforces the same idea. Under 42 CFR § 423.153(d), Part D sponsors must offer a minimum level of MTM services that includes interventions for both beneficiaries and prescribers and quarterly targeted medication reviews (TMRs) with follow-up interventions when necessary. The clinical model and the CMS program rules both expect a closed loop.


Intervention: Acting on Medication-Related Problems

An intervention is a deliberate action taken to resolve or mitigate a medication-related problem (MRP). Interventions may be directed to:

  • The patient (education, adherence tools, self-monitoring, clarification of instructions)
  • The prescriber or care team (recommend dose change, discontinue a drug, add monitoring, switch therapy)
  • The pharmacy/dispensing process (clarifying directions, synchronizing fills, resolving access barriers—within scope)
Intervention typeTypical triggerWho decidesExample
Patient education / counselingKnowledge gap, technique error, fear of side effectsPharmacist (tech may schedule and prepare materials)Teach-back on inhaler technique; explain why a statin is continued after mild myalgia workup
Adherence supportMissed doses, late refills, cost barriersPharmacist designs plan; tech implements logisticsPill organizer + reminder; 90-day supply request; manufacturer assistance referral
Prescriber consultNeeds order change or clinical judgment beyond OTC advicePharmacistFax/secure message recommending stop of duplicate ACE inhibitor
Monitoring recommendationLabs/vitals needed to assess safety/effectivenessPharmacistRequest BMP after starting an ACE inhibitor; BP log review
Therapy clarificationAmbiguous directions, conflicting labelsPharmacist with tech fact-findingConfirm “take with food” timing after discharge

Hard boundary: Technicians gather facts, draft message templates for pharmacist review, transmit pharmacist-approved communications, and log statuses. Technicians do not independently recommend stopping a prescription drug, changing a dose, or diagnosing the clinical cause of an adverse effect.


Referral: When Another Professional Must Own the Next Step

A referral transfers responsibility for a needed action to another clinician or setting. Referral is appropriate when:

  • The problem requires medical diagnosis or prescribing outside pharmacy collaborative practice authority
  • Specialty care is needed (e.g., anticoagulation clinic, endocrinology, behavioral health, pain management)
  • Urgent/emergent symptoms suggest the patient needs immediate medical evaluation, not a routine MTM call-back
  • Care coordination (home health, case management, social work) is required to address social determinants that block safe medication use
SituationPrefer intervention in-pharmacyPrefer referral
Patient uses OTC NSAID with heart failure; willing to stopPharmacist educates; MAP: stop ibuprofen; acetaminophen as directed; notify PCPIf chest pain/edema worsening → urgent medical evaluation
Suspected new drug allergy with rash + breathing difficultySupportive documentation and triageEmergency/urgent care referral immediately
Persistent uncontrolled A1C despite adherence coachingPharmacist recommends regimen review to PCPEndocrinology referral if plan/pharmacist triage indicates
Patient cannot afford insulin and needs benefits navigationPharmacy assistance workflowsSocial work / plan case management referral

Intervention and referral are often paired: the pharmacist intervenes with a recommendation and refers the patient to the clinic for evaluation. The MAP should tell the patient what they can do while waiting; the clinical note should show what the care team was asked to do.


Documentation and Follow-Up as One Core Element

In the APhA/NACDS sequence, element 5 is documentation and follow-up—not “documentation or follow-up.” Documentation without follow-up leaves interventions unfinished. Follow-up without documentation cannot be audited, billed, or safely continued by another team member.

Follow-up purposes:

  1. Confirm the patient completed MAP actions
  2. Confirm the prescriber responded (accepted, modified, or declined recommendations)
  3. Reassess symptoms, adherence, labs, or vitals tied to the MRP
  4. Detect new problems created by the change
  5. Update the PMR/MAP and close or escalate open issues

Typical timelines (program-dependent, clinically driven):

Follow-up focusCommon timingTech support role
High-risk safety change (e.g., stop interacting drug)Days to ~1–2 weeksSchedule call; log attempts; escalate no-answer
Adherence plan after CMR~1–2 weeksStructured outreach checklist; document barriers
Await lab/clinic visitTied to appointment dateReminder before visit; capture results when available
Quarterly TMR-driven issuePer TMR cycle + anytime when necessaryQueue TMR alerts; track “follow-up needed” flags

CMS expects quarterly TMRs with follow-up interventions when necessary. A TMR is focused on specific actual or potential MRPs; it is distinct from a full annual CMR, but it still can generate beneficiary or prescriber follow-up actions that must be tracked.


Technician Support: Tracking Follow-Ups Like a Clinical Operations Engine

High-performing MTM teams treat open interventions as a work queue, not a memory exercise. Technicians are often the people who keep that queue honest.

Practical tracking tasks

  • Maintain a pending intervention log (patient ID, MRP summary code, date sent, channel, responsible pharmacist, due date, status)
  • Schedule follow-up encounters and reminder tasks in the MTM platform
  • Document outreach attempts (date/time, method, outcome: reached / left message / wrong number / declined)
  • Pull refill history, claim status, and prior notes so the pharmacist’s follow-up call is informed
  • Flag overdue items for pharmacist triage daily or per site SOP
  • After resolution, help update PMR/MAP drafts and ensure the chart shows closure reason

Status vocabulary that keeps teams aligned

StatusMeaningNext action
DraftedMessage/note prepared, not sentPharmacist review/send
Sent – awaiting responsePrescriber/patient contactedFollow-up on due date
Patient reached – pending behavior changeAgreed to MAP actionConfirm completion at follow-up
Accepted / completedRecommendation implemented or MAP doneUpdate docs; close or monitor
Declined / deferredPatient or prescriber declinedDocument rationale; escalate if safety-critical
Unable to reachExhausted outreach attempts per SOPAlternate channel; escalate; document

Scenario — Closing the loop

Ms. Patel’s CMR finds duplicate therapy: two pharmacies filling different ACE inhibitors. The pharmacist sends a prescriber intervention recommending consolidation. The technician:

  1. Logs the fax/secure message with date and attachment ID
  2. Sets a 5-business-day follow-up task
  3. On day 5, checks for reply; if none, initiates a second contact per SOP and notifies the pharmacist
  4. When the clinic accepts the change, helps update the PMR, confirms the discontinued Rx is inactivated, and schedules a 2-week adherence check
  5. Documents each step so an auditor can reconstruct the timeline

Without technician tracking, “we faxed them” becomes a black hole—exactly what Domain 3 questions punish.


Linking Interventions to MAP and Patient Experience

Patient-facing MAP items and clinician-facing interventions must stay consistent:

  • If the pharmacist recommends stopping a drug pending clinic approval, the MAP should not instruct the patient to stop unilaterally unless that instruction was clinically approved and clearly communicated
  • If the intervention is educational only, the MAP can carry the patient actions immediately
  • Follow-up questions should reference the MAP (“Were you able to set the evening alarm for metformin?”) rather than vague “How are your meds?”

Effective follow-up uses open-ended questions and teach-back, not a one-way reminder blast. Passive mass texts alone are weak substitutes for structured MTM follow-up when the goal is to evaluate barriers and outcomes.


Exam Traps

  • Treating “identified MRP” as complete without intervention/referral
  • Confusing referral (hand off care) with prescriber intervention (recommend a change while remaining in the MTM episode)
  • Assuming technicians may close clinical recommendations without pharmacist oversight
  • Skipping follow-up after a CMR adherence finding
  • Believing a declined CMR ends all MTM obligations (CMS still expects other required services such as TMRs and interventions—covered further in Chapter 11)
Loading diagram...
Intervention → Follow-Up Closed Loop

Role Clarity Checklist Before You Move On

QuestionIf “yes,” owner is usually…
Does therapy need to change by prescription?Pharmacist intervention ± referral to prescriber
Can the patient act safely today with education/tools?Pharmacist-directed patient intervention + MAP
Is the patient unstable or emergent?Referral to urgent/emergent care
Who ensures the fax gets a response by Friday?Technician tracking + pharmacist escalation
Who decides the clinical recommendation text?Pharmacist / qualified provider

Master this division of labor and you will answer both workflow and patient-safety items in Domain 3 with confidence.

Test Your Knowledge

Which statement best describes the APhA/NACDS core element “intervention and/or referral”?

A
B
C
D
Test Your Knowledge

A CMR finds the patient started daily ibuprofen while taking apixaban. The pharmacist sends a secure message to the prescriber recommending discontinuation of the NSAID and safer pain options. What is the technician’s most appropriate next responsibility?

A
B
C
D
Test Your Knowledge

When is referral the most appropriate path rather than handling the issue solely as an in-pharmacy patient education intervention?

A
B
C
D
Test Your Knowledge

One to two weeks after a CMR identified nonadherence and created MAP actions, which follow-up approach best matches MTM core-element expectations?

A
B
C
D